RT Journal Article
T1 Mechanistic insights and therapeutic strategies for targeting autophagy in pancreatic ductal adenocarcinoma
A1 Michetti, Federica
A1 Cirone, Mara
A1 Strippoli, Raffaele
A1 D’Orazi, Gabriella
A1 Cordani, Marco
AB Pancreatic ductal adenocarcinoma (PDAC) is characterised by early metastasis and resistance to anti-cancer therapy, leading to an overall poor prognosis. Macroautophagy (hereinafter referred to as autophagy) is a conserved cellular homeostasis mechanism that degrades various cargoes (e.g., proteins, organelles, and pathogens) mainly playing a role in promoting survival under environmental stress. Autophagy is an essential defense mechanism against PDAC initiation, acting on multiple levels to maintain cellular and tissue homeostasis. However, autophagy is also intimately involved in the molecular mechanisms driving PDAC progression, facilitating the adaptation of cancer cells to the tumor microenvironment's harsh conditions. In this review, we examine the complex role of autophagy in PDAC and assess the potential of modulating autophagy as a therapeutic strategy. By reviewing current research and clinical trials, we seek to elucidate how targeting autophagy can disrupt PDAC tumor survival mechanisms, enhance the efficacy of existing treatments, and ultimately improve patient outcomes.
PB Springer
SN 2730-6011
YR 2025
FD 2025-04-23
LK https://hdl.handle.net/20.500.14352/120638
UL https://hdl.handle.net/20.500.14352/120638
LA eng
NO Michetti, F., Cirone, M., Strippoli, R., D'Orazi, G., & Cordani, M. (2025). Mechanistic insights and therapeutic strategies for targeting autophagy in pancreatic ductal adenocarcinoma. Discover Oncology, 16, 592. https://doi.org/10.1007/s12672-025-02400-x.
NO M.C. is supported by grant RYC2021–031003I funded by MICIU/AEI /https://doi.org/10.13039/501100011033 and, by European Union Next Generation EU/PRTR. R.S. was funded by AIRC (Associazione Italiana per la Ricerca sul Cancro) (IG26394), the Italian Ministry of Health “Ricerca corrente linea 2” I.N.M.I. L. Spallanzani IRCCS and PRIN 2022 PNRR (P2022XZKBM) financed by the European Union Next Generation.
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Agencia Estatal de Investigación (España)
NO Unión Europea
NO Associazione Italiana per la Ricerca sul Cancro (Italia)
NO Ministero della Salute (Italia)
DS Docta Complutense
RD 23 ene 2026